Adagene's Price Target Adjusted Down to $7.00 by HC Wainwright Amidst Analyst Ratings

Adagene (ADAG) analyst ratings maintain 'Buy' with a price target adjusted from $8.00 to $7.00 USD, a 12.50% decrease. HC Wainwright & Co. analyst Arthur He made this revision, and the average target price for ADAG is $9.64 with a high estimate of $21.07 and a low estimate of $3.50. The average target implies an upside of 379.73% from the current price of $2.01.

Adagene Inc. (NASDAQ: ADAG) has seen a revision in its analyst ratings, with HC Wainwright & Co. analyst Arthur He lowering the price target from $8.00 to $7.00 USD. Despite this adjustment, the stock maintains a "buy" rating, indicating a potential upside of 248.26% based on the current price of $2.01 [1].

The revised price target reflects a 12.50% decrease, aligning with recent regulatory milestones and strategic partnerships. Adagene's recent FDA meeting provided clarity on the development path for its lead program, muzastotug (ADG126), which is now in Phase 2 trials in combination with pembrolizumab for microsatellite stable colorectal cancer (MSS-CRC) patients [2].

The average target price for ADAG is $9.64, with a high estimate of $21.07 and a low estimate of $3.50. This average target implies an upside of 379.73% from the current price of $2.01. Other analysts have also shown interest in ADAG, with Leerink Partners initiating coverage with an "outperform" rating and a $7.00 price target [1].

Investors should consider the recent developments, including strategic partnerships and clinical trial advancements, when evaluating Adagene's potential. The company's debt-to-equity ratio of 0.01 and strong liquidity ratios (current ratio of 2.29, quick ratio of 2.30) indicate a solid financial position [1].

References:
[1] https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-adagene-nasdaqadag-stock-price-2025-08-15/
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-lowers-adagene-stock-price-target-to-7-on-development-path-clarity-93CH-4195188